Product Name: Human IL17A, IL-17F, IL17AF Antibody (Bimekizumab, Research Use)
Catalog Number: NBR-0964
Target Name: IL17A, IL-17F, IL17AF
Trade Name: Bimekizumab
Antibody Drug Description: Bimekizumab is the first-in-class monoclonal antibody designed to simultaneously target IL-17A and IL-17F. Bimekizumab is currently in clinical development for psoriasis, psoriatic arthritis, and ankylosing spondylitis, with promising results. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: CTLA-8
Synonyms: IL-17A; IL-17; CTLA8
Target Description: IL17A (Interleukin 17A) is a Protein Coding gene. Diseases associated with IL17A include Allergic Contact Dermatitis and Bronchiolitis Obliterans. Among its related pathways are MIF Mediated Glucocorticoid Regulation and TGF-Beta Pathway. Gene Ontology (GO) annotations related to this gene include cytokine activity. An important paralog of this gene is IL17F.
Ensembl: ENSG00000112115
Uniprot: Q16552